Salute e Benessere

Novartis appoints Patrick Horber, M.D., President, International as Marie-France…

After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of NovartisDr. Horber to drive next phase of international growth, shape commercial strategy, and continue Novartis leadership in reimagining medicines for patients around the world Basel, September 06, 2023— Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial...
Nasdaq GlobeNewswire
06/09/2023

Idorsia reacquires the world-wide rights to aprocitentan

Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia's oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resistant hypertension.Idorsia will pay Janssen a conditional consideration up to a total cap of CHF 306 millionIdorsia is initiating activities to determine the best approach to maximize the value of aprocitentan.Allschwil, Switzerland – September 6 , 2023Idorsia Ltd (SIX: IDIA) today...
Nasdaq GlobeNewswire
06/09/2023

Sequana Medical Notice of 2023 Half-year Results and Business Update

Ghent, Belgium – 6September2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its half-year results ended 30 June 2023 on Thursday, 14 September 2023.The management team will host a conference call with live webcast at 03:00 pm CEST / 09:00 am EST on the day of the results.The webcast can be accessed by registering on the...
Nasdaq GlobeNewswire
06/09/2023

Addex Announces Participation in the H.C. Wainwright 25th Annual Global…

Geneva, Switzerland,September 6 , 2023 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending theH.C. Wainwright 25th Annual Global Investment Conference (September 11 – 13, 2023)in New York. A pre-recorded corporate presentation is scheduled for viewing on Monday, September 11, 2023, at 07:00 EDT...
Nasdaq GlobeNewswire
06/09/2023

ONWARD Schedules Webcast to Provide Half Year 2023 Business Update

The webcast will be held on September 19, 2023, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver and CFO Lara Smith Weber, who will discuss highlights from Half Year 2023 and provide a business update.To join the webcast via Zoom, please register using thislink.Participants may also join by phone:+32 2 290 9360 (Belgium) +49 69 3807 9884 (Germany) +31 20 794 0854 (Netherlands) +41 22 591 0156 (Switzerland) +44 203 481 5240 (United Kingdom) +1 346 248 7799…
Nasdaq GlobeNewswire
06/09/2023

Polycythemia Vera Market Grow Rapidly at a CAGR of 14% During the Study Period…

Key Takeaways from the Polycythemia Vera Market Report Key Takeaways from the Polycythemia Vera Market Report Discover which therapies are expected to grab the major polycythemia vera market share @Polycythemia Vera Market Report Polycythemia Vera Overview Polycythemia vera, a rare and chronic blood disorder, is characterized by the overproduction of red blood cells, white blood cells, and platelets in the bone marrow. This condition leads to an increase in blood volume and...
PR Newswire
05/09/2023

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11 th−13 thin New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on Tuesday, September 12 that 4:00 pm...
Nasdaq GlobeNewswire
05/09/2023

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 08/31/202355,583,76861,519,936About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T...
Nasdaq GlobeNewswire
05/09/2023

Nyxoah to Participate in Upcoming Investor Conferences

Nyxoah toParticipate in Upcoming Investor ConferencesMont-Saint-Guibert, Belgium – September5 , 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in two upcoming investor conferences in New York City.Olivier Taelman, Nyxoah's Chief...
Nasdaq GlobeNewswire
05/09/2023

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of…

PARIS and CAMBRIDGE, Mass., Sept.05, 2023(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and...
Nasdaq GlobeNewswire
05/09/2023

GENFIT to Participate in Upcoming Investor Conferences

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) ,September05 ,2023– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.Morgan Stanley 21st Annual Global Healthcare Conference Date: September 11-13, 2023 Location: New York H.C. Wainwright 25th...
Nasdaq GlobeNewswire
05/09/2023

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and…

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferencesLyon (France) and Cambridge (MA, US) , September5 , 2023–10:05 p.m. CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (the "Company") ,today publishes its cash position as of June 30, 2023 , and its financial calendar for the second half of 2023 . Cash position as of June 30, 2023As of...
Nasdaq GlobeNewswire
05/09/2023

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

"We are profoundly encouraged by the outcomes of this trial and the evident benefits our hair care cream brought to the participants," said Iris Bincovich, CEO of Innocan. "Our dedication remains unwavering: to innovate and deliver products that genuinely make a difference in people's lives, and this achievement underscores that commitment."The 120-day Trial engaged a diverse group of male and female volunteers experiencing non-seasonal hair loss. The Trial's primary…
PR Newswire
05/09/2023

Alkermes to Participate in Two Upcoming Investor Conferences

Date/Time:Monday, September 11, 2023 at 11:20 a.m. EDT (4:20 p.m. BST) Date/Time:Monday, September 11, 2023at11:20 a.m. EDT( 4:20 p.m. BST ) Cantor Fitzgerald Global Healthcare Conference Date/Time:Wednesday, September 27, 2023at11:30 a.m. EDT( 4:30 p.m. BST ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical...
PR Newswire
05/09/2023

The opportunity within the DNA Encoded Library Market to grow at 16% CAGR till…

Owing to its access to the largest chemical space available in the market, DNA encoded chemical library platforms are a natural fit for big data analytics and modeling technologies offered by artificial intelligence and machine learning. As a result, some companies have been pursuing this opportunity by integrating artificial intelligence and machine learning in DNA encoded libraries, including Insitro, a leading player in machine learning for drug discovery, which acquired Haystack Sciences in…
PR Newswire
05/09/2023

The clinical trial patient recruitment and retention services market is…

Amongst several known challenges, patient recruitment is considered to be one of the rate limiting steps when it comes to getting drugs to the market. Presently, more than 155 companies have the required capabilities to offer patient recruitment and retention services across different geographical locations. Such clinical trial recruitment companies employ a variety of outreach methods and, over time, have attained a vital role in the successful conduct of clinical research. Further, several…
PR Newswire
05/09/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2023

Aggregatedpresentationbydayandbymarket NameofissuerIdentificationcodeof issuer(Legal Entity Identifier)Day of transactionIdentificationcodeof financialinstrumentAggregated daily volume(innumber of shares)Dailyweightedaveragepriceof the purchased shares *Market(MICCode) IPSEN549300M6SGDPB4Z94P1128/08/2023FR0010259150201120.14CEUXIPSEN549300M6SGDPB4Z94P1128/08/2023...
Nasdaq GlobeNewswire
05/09/2023

Healthcare Services Industry's Top Trending Markets - By The Business Research…

In this dynamic and rapidly evolving landscape, businesses operating within the healthcare services sector require accurate and up-to-date market insights to stay competitive and make informed decisions. In this dynamic and rapidly evolving landscape, businesses operating within the healthcare services sector require accurate and up-to-date market insights to stay competitive and make informed decisions. Reports from The Business Research Company (TBRC) serve as invaluable resources for...
PR Newswire
05/09/2023

Transactions in connection with share buy-back program

Company announcement no. 46 - 235 September 2023 Transactions in connection with share buy-back program On 3 August 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 38 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
05/09/2023

Plasma Fractionation Market worth $40.4 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284 Browse in-depth TOC on "Plasma Fractionation Market" 380 - Tables 46 - Figures 331 - Pages Plasma Fractionation Market Scope: The immunoglobins segment accounted for the largest share by-product in the plasma fractionation market in 2022. Based on product, the...
PR Newswire
05/09/2023

Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US

Approximately 40% of all screened patients carry the genetic HLA DR3-DQ2 haplotype. This proportion aligns well with expectations based on previous Diamyd® clinical trials and published epidemiological research. Supported by published retrospective analyses and prospective clinical trials, the presence of the genetic HLA DR3-DQ2 haplotype determines the likelihood of responding to Diamyd® therapy, and serves as one of the main inclusion criteria in the DIAGNODE-3 trial. Approximately 40% of...
PR Newswire
05/09/2023

The opportunity associated with the pharmaceutical polymers / medical polymers…

Polymers have been employed in various fields, such as automotive, agriculture, construction, electronics, medical and textile. Specifically, in the pharmaceutical / medical sector, they find application as excipients in medicinal formulations, medical device components and packaging material, for dosage forms. Further, various stakeholders have developed innovative pharmaceutical / medical polymers, such as biodegradable polymers, stimuli-responsive polymers, shape memory polymers and…
PR Newswire
05/09/2023

Testing, Inspection, And Certification (TIC) Market size worth USD 389.79…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=3794 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=3794 Browse in-depth TOCon" Testing, Inspection, And Certification (TIC) Market " 202 - Pages 126 – Tables 37 – Figures The Global Testing, Inspection, and Certification (TIC) Market: Unveiling Growth Prospects, Key Players, and Market Drivers The Testing, Inspection, And Certification...
PR Newswire
05/09/2023

SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring

"The purpose for developing the SIBIO KS1 CKM was to expand the previous biometric sensing technology SIBIONICS has already mastered to provide higher quality and more precise monitoring capabilities. Since blood ketone levels are one of the key indicators that individuals with certain lifestyles and dietary requirements are paying more attention to these days, the KS1 was the next logical step for R&D at SIBIONICS. With this breakthrough, blood ketone levels can now be monitored in a…
PR Newswire
05/09/2023
Altri  Comunicati